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Background
In some randomized trials comparing revascularization strategies for patients with 
diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than 
percutaneous coronary intervention (PCI). We sought to discover whether aggres-
sive medical therapy and the use of drug-eluting stents could alter the revascular-
ization approach for patients with diabetes and multivessel coronary artery disease.
Methods
In this randomized trial, we assigned patients with diabetes and multivessel coronary 
artery disease to undergo either PCI with drug-eluting stents or CABG. The patients 
were followed for a minimum of 2 years (median among survivors, 3.8 years). All 
patients were prescribed currently recommended medical therapies for the control of 
low-density lipoprotein cholesterol, systolic blood pressure, and glycated hemoglobin. 
The primary outcome measure was a composite of death from any cause, nonfatal 
myocardial infarction, or nonfatal stroke.
Results
From 2005 through 2010, we enrolled 1900 patients at 140 international centers. 
The patients’ mean age was 63.1±9.1 years, 29% were women, and 83% had three-
vessel disease. The primary outcome occurred more frequently in the PCI group 
(P = 0.005), with 5-year rates of 26.6% in the PCI group and 18.7% in the CABG 
group. The benefit of CABG was driven by differences in rates of both myocardial 
infarction (P<0.001) and death from any cause (P = 0.049). Stroke was more frequent 
in the CABG group, with 5-year rates of 2.4% in the PCI group and 5.2% in the 
CABG group (P = 0.03).
Conclusions
For patients with diabetes and advanced coronary artery disease, CABG was supe-
rior to PCI in that it significantly reduced rates of death and myocardial infarction, 
with a higher rate of stroke. (Funded by the National Heart, Lung, and Blood Insti-
tute and others; FREEDOM ClinicalTrials.gov number, NCT00086450.)
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evascularization for patients with 
multivessel coronary artery disease is per-
formed commonly throughout the world. 
In the United States alone, approximately 700,000 
patients undergo multivessel coronary revascular-
ization yearly. Of these patients, 25% have diabe-
tes.1,2 In the Bypass Angioplasty Revascularization 
Investigation (BARI) trial, patients with diabetes 
and multivessel disease who underwent coronary-
artery bypass grafting (CABG) lived longer than did 
patients undergoing balloon angioplasty, a finding 
that led to guideline recommendations for CABG 
as the preferred approach for revascularization in 
such patients.3,4 Outcomes from CABG improved 
with the advent of antithrombotic therapy and the 
use of arterial conduits.5,6 In subsequent years, 
despite major advances in percutaneous coronary 
intervention (PCI) and accompanying medical ther-
apy, studies have consistently shown a trend to-
ward more frequent major adverse cardiovascular 
and cerebrovascular events in patients with diabe-
tes and multivessel coronary artery disease who 
underwent PCI than among those who underwent 
CABG. Most recently, in the era of drug-eluting 
stents, a small, underpowered, randomized trial, 
the Coronary Artery Revascularization in Diabetes 
(CARDia) study, and a subgroup analysis of the 
Synergy between PCI with TAXUS and Cardiac 
Surgery (SYNTAX) study showed an increased rate 
of major adverse cardiovascular and cerebrovas-
cular events at 12 months for patients with mul-
tivessel disease who underwent PCI with drug-
eluting stents, as compared with CABG.7,8 In 
SYNTAX, there was further divergence of the event 
curves during long-term follow-up.9
In the Future Revascularization Evaluation in 
Patients with Diabetes Mellitus: Optimal Manage-
ment of Multivessel Disease (FREEDOM) trial, we 
used contemporary PCI and CABG techniques and 
currently recommended ancillary medical thera-
pies to determine whether CABG or PCI with 
drug-eluting stents is the superior approach to 
revascularization in patients with diabetes and 
multivessel coronary artery disease.
Methods
Patient Selection and Randomization
The study enrolled patients with diabetes and an-
giographically confirmed multivessel coronary ar-
tery disease with stenosis of more than 70% in 
two or more major epicardial vessels involving at 
least two separate coronary-artery territories and 
without left main coronary stenosis. A full descrip-
tion of the methods was published previously,10 and 
the protocol is available with the full text of this 
article at NEJM.org. Randomization was conducted 
in a 1:1 ratio with the use of permuted blocks with 
dynamic balancing within each study center.
Measurements
Patients underwent routine assessment of angina 
and neurologic status and cardiac markers. All 
patients were screened for stroke with the Na-
tional Institutes of Health (NIH) Stroke Scale11 
and the Rankin scale12 at each follow-up visit for 
12 months in order to detect strokes that might 
not have been reported. Minimum follow-up for 
all patients was 2 years, and the first enrolled 
patients were followed for 6.75 years. A core lab-
oratory reading of all qualifying angiograms was 
conducted at the Cardiovascular Research Foun-
dation in New York.
Revascularization and Pharmacologic 
Therapy
Sirolimus-eluting and paclitaxel-eluting stents, 
which were provided to the patients free of charge, 
were the predominant types of drug-eluting stents 
that were used in the trial, according to the tim-
ing of the study. The study protocol recommend-
ed that only one type of drug-eluting stent should 
be used in a given patient. A newer generation of 
drug-eluting stents could be used in the trial as 
long as they were approved for use. The use of 
abciximab was recommended for patients under-
going PCI and also was provided to the patients 
free of charge. The use of dual antiplatelet therapy 
with aspirin and clopidogrel (also provided free of 
charge) was recommended for at least 12 months 
after stent implantation. For CABG surgery, arte-
rial revascularization was encouraged. It was rec-
ommended that the following guideline-driven 
targets be used for lowering medical risk factors: 
low-density lipoprotein cholesterol, lower than 
70 mg per deciliter; blood pressure, lower than 
130/80 mm Hg; and glycated hemoglobin, lower 
than 7%. Regular communication with the treating 
physicians regarding control of risk factors was 
maintained throughout the course of the trial.
Trial Outcomes
The primary outcome was a composite of death 
from any cause, nonfatal myocardial infarction, 
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and nonfatal stroke. In the first 30 days after the 
primary or any repeat revascularization proce-
dure, myocardial infarction was defined as the 
presence of new Q waves in 2 or more contiguous 
leads on electrocardiography, as compared with 
baseline. Following the first 30 days after any 
revascularization procedure, myocardial infarc-
tion was defined as either a typical increase in 
the troponin level or a more rapid rise and fall in 
the MB fraction of creatine kinase (CK-MB) with 
the presence of one or more of the following fac-
tors: ischemic symptoms, development of patho-
logic Q waves on electrocardiography, changes 
indicative of ischemia on electrocardiography, 
the need for repeated coronary-artery interven-
tion, or pathologic findings of an acute myocar-
dial infarction.
Stroke was defined as the presence of at least 
one of the following factors: a focal neurologic 
deficit of central origin lasting more than 72 hours 
or lasting more than 24 hours with imaging evi-
dence of cerebral infarction or intracerebral hem-
orrhage, a nonfocal encephalopathy lasting more 
than 24 hours with imaging evidence of cerebral 
infarction or hemorrhage adequate to account for 
the clinical state, or retinal arterial ischemia or 
hemorrhage. Strokes were graded with the NIH 
11-item Stroke Scale (with a score of >4 indicat-
ing a disabling stroke) and the Rankin scale 
(ranging from 1 to 5, with higher scores indicat-
ing greater disability). The definitions of all trial 
end points are listed in the Supplementary Ap-
pendix, available at NEJM.org.
Key secondary outcome measures included the 
rate of major adverse cardiovascular and cerebro-
vascular events 30 days and 12 months after the 
procedure (including components of the primary 
outcome as well as repeat revascularization) and 
annual all-cause and cardiovascular mortality. We 
also examined categories for the SYNTAX score 
(≤22, 23 to 32, or ≥33, with a score of ≥33 indi-
cating extensive disease) and study-center loca-
tion in North America, as compared with not in 
North America. An events committee provided 
central independent adjudication of all occur-
rences of the primary end points in an unblind-
ed fashion.
Trial Oversight
The study was sponsored by the National Heart, 
Lung, and Blood Institute (NHLBI). Cordis, John-
son & Johnson, and Boston Scientific provided the 
stents; Eli Lilly provided abciximab and an unre-
stricted research grant; and Sanofi-Aventis and 
Bristol-Myers Squibb provided clopidogrel.
The steering committee was solely responsible 
for the design and conduct of the study, along with 
the analysis of the data and the decision to submit 
the manuscript for publication. The committee 
vouches for the accuracy and completeness of the 
data analysis and attests to the fidelity of this 
report to the study protocol. 
Statistical Analysis
We adopted two amendments to the study proto-
col with respect to the target sample size. The trial 
was originally designed to enroll 2400 patients 
during a 2-year period with minimum follow-up 
of 3 years per patient to ensure a power of 85% to 
detect a relative reduction of 18 to 23% in 4-year 
rates of the primary outcome, which were expect-
ed to range from 30 to 38% in the less effective 
study group. In December 2007, the protocol was 
amended to have a target enrollment of 2058 pa-
tients during a 4.25-year period with a minimum 
of 2.5 years of follow-up to ensure a power of 85% 
to detect a relative reduction of 24.6% in the rate 
of the primary outcome, with 1% crossover and 
loss to follow-up. In April 2009, the protocol was 
again amended to have a final target enrollment 
of 1900 patients during a 4.75-year period with a 
minimum of 2 years of follow-up. These calcula-
tions were based on an observed aggregate 4-year 
event rate of 14.85%, with an estimated power of 
80% to detect a relative reduction of 27% in the 
4-year event rates in the two study groups.
Clinical event rates for the primary outcome 
and for cardiovascular death were based on the 
time since randomization. The secondary trial 
end points of major adverse cardiovascular and 
cerebrovascular events at 30 days and 12 months 
were based on the time since the procedure. We 
calculated the time since the procedure accord-
ing to the date of the initial index procedure for 
both single and staged procedures. We used the 
log-rank test to compare the distributions of the 
time to the first event for the primary and sec-
ondary outcomes according to study-group assign-
ment using all available follow-up data. We used 
Cox proportional-hazards regression to determine 
hazard ratios for selected outcomes and to con-
duct prespecified subgroup analyses of the pri-
mary outcome, using a test of study-group as-
signment according to subgroup interaction.
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All between-group comparisons were conduct-
ed according to the intention-to-treat principle. 
Interim analyses were planned to be conducted 
when 25%, 50%, and 75% of data were available, 
with the fraction calculated on the basis of the 
accrual of potential follow-up data. A final P value 
of less than 0.044 was considered to indicate sta-
tistical significance for the primary outcome on 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
PCI 
(N = 953)
CABG 
(N = 947) P Value†
Age at randomization — yr 63.2±8.9 63.1±9.2 0.78
Male sex — no. (%) 698 (73.2) 658 (69.5) 0.08
Glycated hemoglobin — % 7.8±1.7 7.8±1.7 0.86
Current smoker — no. (%) 141 (14.8) 157 (16.6) 0.31
Previous myocardial infarction — no. (%) 250 (26.2) 237 (25.0) 0.56
Recent acute coronary syndrome — no. (%) 304 (31.9) 279 (29.5) 0.25
Three-vessel disease — no./total no. (%) 780/948 (82.3) 793/939 (84.5) 0.22
Left ventricular ejection fraction
Percent 65.7±12.1 66.6±10.5 0.13
<40% — no./total no. (%) 21/641 (3.3) 11/650 (1.7) 0.07
EuroSCORE‡ 0.52
Mean 2.7±2.4 2.8±2.5
Median (interquartile range) 1.9 (1.3–3.1) 2.0 (1.3–3.3)
SYNTAX score§ 0.77
Mean 26.2±8.4 26.1±8.8
Median (interquartile range) 26.0 (20.5–31.0) 26.0 (19.5–31.5)
Category — no./total no. (%) 
Low: ≤22 329/949 (34.7) 340/938 (36.2)
Intermediate: 23–32 438/949 (46.2) 406/938 (43.3)
High: ≥33 182/949 (19.2) 192/938 (20.5) 0.45
No. of lesions 5.65±2.16 5.74±2.19 0.33
Chronic total occlusion — no./total no. (%)¶ 323/5564 (5.8) 329/5662 (5.8) 0.99
Bifurcation — no./total no. (%)¶ 1242/5561 (22.3) 1177/5640 (20.9) 0.06
Use of insulin — no./total no. (%) 322/952 (33.8) 293/947 (30.9) 0.19
Use of thiazolidinedione — no./total no. (%) 73/952 (7.7) 82/947 (8.7) 0.45
Staged procedure — no./total no. (%) 321/939 (34.2) NA NA
Total no. of lesions stented across all stages 3.5±1.4 NA NA
Total length of stents placed — mm 26.1±14.2 NA NA
Surgery off-pump — no./total no. (%) NA 165/893 (18.5) NA
No. of graft vessels NA 2.9±0.8 NA
Left internal thoracic-artery graft — no./total no. (%) NA 848/898 (94.4) NA
* Plus–minus values are means ±SD. NA denotes not applicable.
† P values were calculated with the use of Fisher’s exact test for categorical variables, the Wilcoxon rank-sum test for the 
European System for Cardiac Operative Risk Evaluation (EuroSCORE) value, and Student’s t-test for the remaining con-
tinuous variables.
‡ A score of 5 or more on the EuroSCORE is associated with decreased rates of survival.
§ A score of 33 or more on the Synergy between PCI with TAXUS and Cardiac Surgery (SYNTAX) scale indicates extensive 
disease.
¶ Values in this category are based on the total number of lesions in 949 patients in the PCI group and 939 patients in 
the CABG group.
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the basis of three interim analyses (performed with 
22%, 46%, and 74% of available data). A P value of 
less than 0.05 was considered to indicate signifi-
cance for all other outcomes. All analyses were 
conducted with the use of SAS software, version 
9.3 (SAS Institute) and S-PLUS 8.0 for Windows 
software (Insightful).
Results
Study Population
From April 2005 through April 2010, a total of 
32,966 patients were screened (Fig. 1 in the Sup-
plementary Appendix). Of the 3309 trial-eligible 
patients, 1900 (57.4%) provided written informed 
consent and underwent randomization. The clini-
cal and angiographic characteristics of the patients 
were well balanced in the two study groups at 
baseline (Table 1). The mean age was 63.1±9.1 
years, and 83% of patients had three-vessel dis-
ease. The mean SYNTAX score was 26.2±8.6 and 
did not differ significantly according to study 
group. Sirolimus-eluting and paclitaxel-eluting 
stents were used exclusively in 51% and 43% of 
patients, respectively, in the PCI group who actu-
ally underwent PCI. The median follow-up time 
was 3.8 years (interquartile range, 2.5 to 4.9).
Cardiac Medications
The use of thienopyridines in particular remained 
higher in the PCI group after 5 years of follow-up. 
However, the use of other evidence-based thera-
pies such as statins, beta-blockers, and angiotensin-
converting–enzyme inhibitors and angiotensin-
receptor blockers was similar in the two study 
groups (Table 1 in the Supplementary Appendix).
Primary Outcome
The primary outcome occurred in 352 patients 
(205 in the PCI group and 147 in the CABG 
group) (Table 2). The rate of the primary out-
come was lower in the CABG group than in the 
PCI group (P = 0.005 by the log-rank test), with 
divergence of the curves starting at 2 years (Fig. 
1A). At 30 days, the primary outcome had oc-
curred in fewer patients in the PCI group than in 
the CABG group (26 vs. 42). However, 5-year 
event rates were 26.6% in the PCI group, as com-
pared with 18.7% in the CABG group, for an ab-
solute difference of 7.9 percentage points (95% 
confidence interval [CI], 3.3 to 12.5). There was 
increased all-cause mortality in the PCI group 
(P = 0.049), with 5-year rates of 16.3% in the PCI 
group versus 10.9% in the CABG group, for an 
absolute difference of 5.4 percentage points (95% 
CI, 1.5 to 9.2) (Fig. 1B).
The distributions of time until myocardial in-
farction also differed in favor of the CABG group 
(P<0.001) (Table 2, and Fig. 2A in the Supplemen-
tary Appendix). At 5 years, 13.9% of patients in 
the PCI group had had a myocardial infarction, 
as compared with 6.0% in the CABG group. 
Periprocedural myocardial infarction occurred 
in 17 patients in the PCI group (17% of the 99 
patients with myocardial infarction in that group) 
and 15 in the CABG group (31% of the 48 pa-
Table 2. Kaplan–Meier Estimates of Key Outcomes at 2 Years and 5 Years after Randomization.
Outcome
2 Years after  
Randomization
5 Years after  
Randomization Patients with Event P Value*
PCI CABG PCI CABG PCI CABG
number (percent) number
Primary composite† 121 (13.0) 108 (11.9) 200 (26.6) 146 (18.7) 205 147 0.005‡
Death from any cause 62 (6.7) 57 (6.3) 114 (16.3) 83 (10.9) 118 86 0.049
Myocardial infarction 62 (6.7) 42 (4.7) 98 (13.9) 48 (6.0) 99 48 <0.001
Stroke 14 (1.5) 24 (2.7) 20 (2.4) 37 (5.2) 22 37 0.03§
Cardiovascular death 9 (0.9) 12 (1.3) 73 (10.9) 52 (6.8) 75 55 0.12
* P values were calculated with the use of the log-rank test on the basis of all available follow-up data (i.e., more than 5 years).
† The primary composite outcome was the rate of death from any cause, myocardial infarction, or stroke.
‡ P = 0.006 in the as-treated (non–intention-to-treat) analysis.
§ P = 0.16 by the Wald test of the Cox regression estimate for study-group assignment in 1712 patients after adjustment 
for the average glucose level after the procedure.
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tients with myocardial infarction in that group). 
All the procedural myocardial infarctions in the 
trial were non–Q-wave events. Myocardial in-
farctions that occurred more than 30 days after 
the index procedures were reported in 81 of 99 
patients (82%) in the PCI group and in 29 of 48 
patients (60%) in the CABG group.
There were fewer strokes in the PCI group 
than in the CABG group (P = 0.03) (Table 2, and 
Fig. 2B in the Supplementary Appendix). The 
5-year rates were 2.4% in the PCI group and 5.2% 
in the CABG group. Of these strokes, the major-
ity (87%) were ischemic and 13% were hemor-
rhagic. In the first 30 days after the procedure, 
3 patients in the PCI group and 16 in the CABG 
group had a stroke (Table 3). The excess of strokes 
in the CABG group occurred in the first 30 days 
after randomization. An NIH Stroke Scale score 
of more than 4 (severely disabling) at the time of 
the event was reported in 27% of patients in the 
PCI group, as compared with 55% of those in 
the CABG group. A score on the Rankin scale of 
more than 1 at the time of the stroke was re-
ported in 60% of patients in the PCI group, as 
compared with 70% in the CABG group.
Secondary Outcomes
Rates of cardiovascular death (63.7% of all deaths) 
did not differ significantly between the two study 
groups (P = 0.12 by the log-rank test), nor did rates 
of major adverse cardiovascular and cerebrovas-
cular events at 30 days (P = 0.68 by the log-rank 
test). However, at 1 year after the procedure, there 
was a significant difference in rates of major ad-
verse cardiovascular and cerebrovascular events, 
with 16.8% in the PCI group versus 11.8% in the 
CABG group (P = 0.004) (Table 3, and Fig. 2C in 
the Supplementary Appendix). This difference was 
attributed largely to the preponderance of repeat 
revascularization events by 1 year in the PCI group, 
as compared with the CABG group, with repeat 
events in 12.6% and 4.8% of patients in the two 
groups, respectively (hazard ratio, 2.74; 95% CI, 
1.91 to 3.89; P<0.001) (Fig. 2D in the Supplemen-
tary Appendix).
Prespecified Subgroup Analyses
The greater benefit of CABG versus PCI was con-
sistent across all prespecified subgroups (Fig. 2). 
The analysis according to the category of SYNTAX 
score showed no significant subgroup interac-
tion (P = 0.58). At 5 years, the absolute difference in 
the rate of the primary outcome in the PCI group, 
as compared with the CABG group, was similar in 
the three SYNTAX subgroups (6 percentage points 
for a low SYNTAX score, 10 percentage points for 
an intermediate score, and 8 percentage points for 
a high score). The hazard ratios for the PCI group, 
as compared with the CABG group, according to 
SYNTAX subgroup were 1.14, 1.46, and 1.46, re-
spectively. Similarly, for the rate of major adverse 
cardiovascular and cerebrovascular events at 1 year, 
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Figure 1. Kaplan–Meier Estimates of the Composite Primary Outcome 
and Death.
Shown are rates of the composite primary outcome of death, myocardial  
infarction, or stroke (Panel A) and death from any cause (Panel B) truncated 
at 5 years after randomization. The P value was calculated by means of the 
log-rank test on the basis of all available follow-up data.
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there was no differential treatment effect accord-
ing to the category of SYNTAX score (P = 0.28 for 
interaction). 
We conducted the primary outcome analysis for 
PCI, as compared with CABG, using data for pa-
tients in whom only paclitaxel-eluting stents were 
used (394 patients) and in whom only sirolimus-
eluting stents were used (469 patients), as com-
pared with 898 patients who underwent CABG. In 
these two analyses, the absolute between-group 
rate differences at 5 years were nearly identical: 6.5 
percentage points for paclitaxel-eluting stents and 
6.7 percentage points for sirolimus-eluting stents.
Safety
A major bleeding event occurred within 30 days 
after the index revascularization procedure in 23 
patients in the PCI group and 34 patients in the 
CABG group (P = 0.13). Acute renal failure requir-
ing hemodialysis within 30 days after the index 
revascularization procedure was observed in 1 pa-
tient in the PCI group and 8 patients in the CABG 
group (P = 0.02).
Discussion
In this study, we compared revascularization strat-
egies for patients with diabetes and multivessel 
(predominantly three-vessel) coronary artery dis-
ease and found that patients who underwent CABG 
had significantly lower rates of the composite 
primary outcome of death from any cause, myocar-
dial infarction, or stroke than did those undergoing 
PCI with a drug-eluting stent. This result was sim-
ilar at all levels of angiographic complexity (accord-
ing to the SYNTAX score13), ejection fraction, and 
renal function.
Our findings are consistent with reports from 
other smaller or retrospective studies of revascu-
larization in patients with diabetes. A significant 
advantage of CABG over balloon angioplasty was 
reported in the mid-1990s in a retrospective 
analysis of the BARI trial.14 This study led to an 
NHLBI alert recommending that patients with 
diabetes and multivessel disease undergo CABG 
as the preferred mode of revascularization.15 How-
ever, clinical practice did not change appreciably 
on the basis of the alert or the subsequent trial 
publication.
Since that time, other trials, including the 
Arterial Revascularization Therapies Study (ARTS) 
(historical control),16 CARDia (underpowered ran-
domized trial), and SYNTAX (subgroup analysis), 
have reported excess rates of major adverse car-
diovascular and cerebrovascular events in patients 
with diabetes who were assigned to undergo PCI 
rather than CABG, although the differences ob-
served in these studies were primarily the result 
of a higher rate of revascularization among pa-
tients undergoing PCI. In contrast, in our study, 
we found that the benefit of CABG was driven by 
reductions in rates of both myocardial infarction 
and death from any cause. Our definition of myo-
cardial infarction is consistent with the recent 
consensus of the American College of Cardiolo-
gy and the American Heart Association with re-
spect to spontaneous myocardial infarction. How-
ever, we used even more stringent criteria for the 
definition of periprocedural myocardial infarc-
tion.17 The observation that CABG was associ-
ated with a higher rate of stroke has been ob-
served in virtually every comparative trial of the 
two treatment strategies, as well as in a recent 
meta-analysis.18
Table 3. Kaplan–Meier Estimates of Major Adverse Cardiovascular and Cerebrovascular Events at 30 Days and 12 Months 
after the Procedure.
Event 30 Days after Procedure 12 Months after Procedure
PCI CABG P Value PCI CABG P Value
number (percent) number (percent)
Major adverse cardiovascular and cerebrovascular 
events
45 (4.8) 47 (5.2) 0.68 157 (16.8) 106 (11.8) 0.004
Death 8 (0.8) 15 (1.7) 0.12 32 (3.4) 38 (4.2) 0.35
Myocardial infarction 17 (1.8) 15 (1.7) 0.82 54 (5.8) 30 (3.4) 0.02
Stroke 3 (0.3) 16 (1.8) 0.002 8 (0.9) 17 (1.9) 0.06
Repeat revascularization 31 (3.3) 10 (1.1) 0.002 117 (12.6) 42 (4.8) <0.001
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Our study has several strengths. We focused 
exclusively on patients with diabetes in a single, 
well-powered, randomized trial, in which we en-
rolled high-risk patients with a good distribution 
of SYNTAX scores and followed those patients 
for clinical cardiovascular events for a median of 
3.8 years. Consistent with the BARI 2 Diabetes 
(BARI-2D) trial, optimal medical therapy was 
prescribed throughout the follow-up.19
A comprehensive meta-analysis of trials per-
formed before the introduction of drug-eluting 
stents showed excess mortality after PCI, as com-
pared with CABG, in patients with diabetes.20 
Although our study was not powered to detect a 
difference in all-cause mortality, we observed a 
significantly (P = 0.049) higher rate in the PCI-
treated group. This was also observed in the small 
subgroup analysis of the BARI trial, and a similar 
trend toward higher mortality has been suggested 
by the other trials. The increased use of internal 
mammary grafting in these trials has been pos-
tulated to play a key role in the improved survival 
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Figure 2. Primary Composite Outcome, According to Subgroup.
Subgroup analyses were performed with the use of Cox proportional-hazards regression. Five-year composite event rates for death, myo-
cardial infarction, or stroke are shown. LAD denotes left anterior descending artery, and LVEF left ventricular ejection fraction.
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with CABG. When considered together, the data 
provide a convincing signal that PCI results in 
increased long-term mortality, as compared with 
CABG, in patients with diabetes and multivessel 
coronary artery disease.
In long-term follow-up, the rate of myocar-
dial infarction was significantly higher in the PCI 
group than in the CABG group, whereas the rate 
of stroke was significantly higher in the CABG 
group. The higher relative risk of stroke among 
patients undergoing CABG was evident only early 
in the postprocedural period.
Concomitant medical therapy is important to 
all patients with diabetes and coronary artery 
disease. In the PCI group, almost 90% of pa-
tients were receiving dual antiplatelet therapy at 
12 months. Unlike in the SYNTAX trial, we ob-
served similar rates of use of most other cardio-
vascular medications in the two study groups. An 
intensive medical program was promoted through-
out the trial as the cornerstone of treatment.
Our study has some limitations. First, since 
some of the prespecified subgroups had very low 
prevalence, the statistical power was low to detect 
interactions between treatment and subgroup. 
Second, since the trial was not blinded, patients 
may have been treated differently on the basis of 
their surgical procedure. However, trial outcomes 
were objective and independently adjudicated, and 
the available data suggest no group differences 
in the appropriateness of the medical therapy re-
ceived. Clearly, there is wide variability as to the 
types of patients enrolled, as shown by the distri-
bution of SYNTAX scores at baseline. This varia-
tion reflects real-world practice and is a strength, 
rather than a weakness, of the study.
In conclusion, we found that CABG was supe-
rior to PCI with drug-eluting stents in patients with 
diabetes and advanced (predominantly three-
vessel) coronary artery disease in that CABG 
significantly reduced rates of death and myocar-
dial infarction, with a higher rate of stroke.
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